The article examines the objective, findings, and clinical context described in FDA clears at-home risankizumab induction.
Approach:
Approval: The FDA approved subcutaneous risankizumab-rzaa (Skyrizi) induction administered at home with an on-body injector.
Evidence: The approval was supported by AFFIRM, a double-blind, placebo-controlled phase 3 trial that randomly assigned 274 adults 2:1 to risankizumab or placebo.
Regimen: The approved induction dose is 720 mg at weeks 0, 2, 4, and 8, followed by subcutaneous maintenance every 8 weeks starting at week 12. Intravenous induction remains an alternative.
Key Findings:
At week 12, clinical remission occurred in 56% of risankizumab recipients and 30% of placebo recipients; endoscopic response occurred in 43% and 15%, respectively.
Endoscopic remission occurred in 26% of risankizumab recipients versus 11% of placebo recipients.
About 65% of participants had prior advanced therapy failure.
The manufacturer reported no new safety risks. Prescribing information advises liver blood tests before and during treatment, including for at least 12 weeks.
Interpretation:
In AFFIRM, subcutaneous risankizumab was superior to placebo for clinical remission and endoscopic response at week 12.
Limitations:
The supplied context reports outcomes through week 12 and does not provide longer-term trial results.
The supplied context does not provide detailed adverse-event rates.
Conclusion:
The FDA also revised tuberculosis precautions across risankizumab indications, allowing providers to use clinical judgment about pretreatment evaluation rather than requiring testing before initiation.
Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.
